About Corvus Pharmaceuticals
Corvus Pharmaceuticals develops ITacitinib and CPI-818 immunotherapy antibodies for treating solid tumors and T-cell lymphomas through novel immune checkpoint mechanisms.
📍 Location & Offices
📋 Request a Quote
Send your requirements directly to Corvus Pharmaceuticals. Response typically within 48 hours.
Company Info
TypePublic
StockCRVS (NASDAQ)
Founded2014
Employees35
Revenue$5M
HQBurlingame, USA
